Neurona Therapeutics’ Post

Sudden Unexpected Death in Epilepsy (SUDEP) remains a critical concern in epilepsy management, with the underlying mechanisms still not fully understood. Our latest blog explores a recent study by Iyer, S., et al (2024) that investigates how altered ventilatory responses to hypercapnia-hypoxia (HH) challenges in a preclinical SUDEP model implicate orexin neurons: https://hubs.ly/Q02Gy87z0 #SUDEP #Orexins #Plethysmography #NeuralControlOfBreathing

RAP-219 is a clinical-stage small molecule designed to achieve neuroanatomical specificity through its selective targeting of a RAP known as TARPγ8, which is associated with the neuronal AMPAR, a clinically validated target for epilepsy. Whereas AMPARs are distributed widely in the CNS, TARPγ8 is expressed only in discrete regions – most enriched in the hippocampus (which is often involved in focal epilepsies) and also present in the amygdala and cortex. Because of this restricted expression of #TARPγ8, we believe #RAP-219 has the potential to provide a differentiated clinical profile, including improved activity and tolerability along with a higher #therapeutic index, potentially providing more patients with #sustained therapeutic benefit without intolerable side effects. #CNS #Innovativebiotech #Innovation #Drugdevelopment #Newmodalities #Epilepsy #IPO #Patientcentricity

Breaking new ground in nerve injury and repair models! MD Biosciences offers preclinical rodent and porcine models for cutting-edge neuropathic pain research, pushing the boundaries of our understanding of pain mechanisms and testing therapeutic applications. Explore our models for peripheral nerve injury and repair, including our translational pig model for peripheral trauma. Read more about the different nerve injury and repair models: https://hubs.la/Q02mrc8x0 #neuropathicpain #painresearch #drugdevelopment #translationalmodels

Sensitivity of the Preclinical Alzheimer’s Cognitive Composite (PACC), PACC5, and Repeatable Battery for Neuropsychological Status (RBANS) to Amyloid Status in Preclinical Alzheimer’s Disease..... Papp, K.V., et al. https://lnkd.in/e4AMKteK #Alzheimerscognitive #Amyloid #Neuropsychological

Precision medicine has the potential to change the landscape of rare disease treatment by creating tailored medications that cater to the specific requirements of individual patients. However, this notion also brings forth unique regulatory obstacles that can stifle the research process and delay product commercialization. What factors make rare neurological disease a target for precision medicine, and how can we overcome key obstacles for these conditions? To learn more, read here: https://lnkd.in/eR3GTVbi #Allucent #BringNewTherapiesToLight #PrecisionMedicine #RareDisease #Neurology

Please join us for the inaugural ADDF Summit: Advancements in Novel Therapeutics and Combination Therapy on Monday, October 28th, preceding #CTAD24. The Summit is an invite-only, full-day meeting that brings together expert collaboration of #scientists from academia and biotech, #industry and #government, and other thought leaders. The symposium will explore cutting-edge science that will accelerate the development of new treatments—guided by the #BiologyOfAging—and advance the field of Alzheimer's disease with innovative approaches around #CombinationTherapy and #PrecisionMedicine. This year’s agenda includes an array of ADDF leadership including CEO Mark Roithmayr, and Co-Founder and Chief Science Officer, Howard Fillit, MD, as well as leading ADDF-funded researchers like Miia Kivipelto, MD, PhD, Jeffrey Cummings, MD, ScD, Henrik Zetterberg, MD, PhD, Miranda Orr, PhD, and more. Funded institutions set to present include C2N Diagnostics, GliaPharm SA, Coya Therapeutics, Inc., Cognito Therapeutics, Inc., and Alzheimer's Research UK. Visit the website to learn more: https://lnkd.in/eSu8EWqr

You can now watch our latest webinar on demand! Our expert user, Dr Brian Gill from Columbia University, shares his latest research on how neuron-glioma interactions contribute to seizures and tumoural growth, and Dr Tony Oosterveen from bit․bio discusses how our neuron co-culture platform can be used to accelerate the study of the principles underlying excitatory-inhibitory neuron imbalances and for the discovery of new drugs. Watch the webinar now: https://hubs.ly/Q02wFFr20 #webinar #research #DrugDiscovery #optiox #ioCells #GABA #epilepsy #schizophrenia #autism #AlzheimersDisease #iPSCs #CNS #data

Market Information - 16/01/2024 Exciting news in the healthcare industry! Genevant has secured a $114M deal with Tome to develop liver therapy. Meanwhile, Allakos has dropped their lead asset after mid-phase flops, leading to a halving of their headcount. In other news, Alto Neurosciences is preparing to go public with their CNS therapies. Additionally, the FDA has cleared an AI that predicts Alzheimer's progression from an MRI. Unfortunately, Novartis has backed out of their deal with Cytokinetics. Stay informed with the latest updates in the healthcare industry. #HealthcareNews #Genevant #Tome #Allakos #AltoNeurosciences #Cytokinetics #FDA #Alzheimers #MRI #HealthcareIndustry

Learn the key considerations for utilizing #RANO 2.0 criteria when assessing #Glioblastoma treatments in #ClinicalTrials. Read the blog by Calyx's Elif Sikoglu https://lnkd.in/dq6H6uCv #MedicalImaging #NeuroOncology #ChooseCalyx

Key point: A first demonstration is made of plasma pNF-H concentration as a biomarker for the development of severe posttraumatic epilepsy. https://lnkd.in/gZPcbsTe